Roth MKM analyst Jason Wittes initiated coverage of Globus Medical with a Buy rating and $75 price target. Globus Medical has established itself as the dominant force in spine with about a 20% market share after joining forces with Nuvasive, and the combined company has market leadership in multiple categories across spine and unprecedented quality and depth across the product portfolio, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMED:
- Globus Medical price target lowered to $58 from $65 at Truist
- Globus Medical price target raised to $86 from $77 at Barclays
- Needham biotechnology analysts to hold an analyst/industry conference call
- Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum
- Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023
